Literature DB >> 27373505

Microglia activation states and cannabinoid system: Therapeutic implications.

M Mecha1, F J Carrillo-Salinas2, A Feliú2, L Mestre2, C Guaza3.   

Abstract

Microglial cells are recognized as the brain's intrinsic immune cells, mediating actions that range from the protection against harmful conditions that modify CNS homeostasis, to the control of proliferation and differentiation of neurons and their synaptic pruning. To perform these functions, microglia adopts different activation states, the so-called phenotypes that depending on the local environment involve them in neuroinflammation, tissue repair and even the resolution of the inflammatory process. There is accumulating evidence indicating that cannabinoids (CBs) might serve as a promising tool to modify the outcome of inflammation, especially by influencing microglial activity. Microglia has a functional endocannabinoid (eCB) signaling system, composed of cannabinoid receptors and the complete machinery for the synthesis and degradation of eCBs. The expression of cannabinoid receptors - mainly CB2 - and the production of eCBs have been related to the activation profile of these cells and therefore, the microglial phenotype, emerging as one of the mechanisms by which microglia becomes alternatively activated. Here, we will discuss recent studies that provide new insights into the role of CBs and their endogenous counterparts in defining the profile of microglia activation. These actions make CBs a promising therapeutic tool to avoid the detrimental effects of inflammation and possibly paving the way to target microglia in order to generate a reparative milieu in neurodegenerative diseases.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cannabinoids; Microglia; Neurodegeneration; Neuroinflammation; Phenotypes; Repair

Mesh:

Substances:

Year:  2016        PMID: 27373505     DOI: 10.1016/j.pharmthera.2016.06.011

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  55 in total

1.  Cannabis: A potential efficacious intervention for PTSD or simply snake oil?

Authors:  Alfonso Abizaid; Zul Merali; Hymie Anisman
Journal:  J Psychiatry Neurosci       Date:  2019-03-01       Impact factor: 6.186

Review 2.  Environmental neurotoxicant-induced dopaminergic neurodegeneration: a potential link to impaired neuroinflammatory mechanisms.

Authors:  Arthi Kanthasamy; Huajun Jin; Adhithiya Charli; Anantharam Vellareddy; Anumantha Kanthasamy
Journal:  Pharmacol Ther       Date:  2019-01-22       Impact factor: 12.310

3.  In Vivo Imaging of Translocator Protein in Long-term Cannabis Users.

Authors:  Tania Da Silva; Sina Hafizi; Jeremy J Watts; Cynthia Shannon Weickert; Jeffrey H Meyer; Sylvain Houle; Pablo Rusjan; Romina Mizrahi
Journal:  JAMA Psychiatry       Date:  2019-12-01       Impact factor: 21.596

Review 4.  Cannabinoids and glial cells: possible mechanism to understand schizophrenia.

Authors:  Valéria de Almeida; Daniel Martins-de-Souza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-02-01       Impact factor: 5.270

Review 5.  Targeting Cannabinoid Receptor 2 on Peripheral Leukocytes to Attenuate Inflammatory Mechanisms Implicated in HIV-Associated Neurocognitive Disorder.

Authors:  Michael D Rizzo; Joseph E Henriquez; Lance K Blevins; Anthony Bach; Robert B Crawford; Norbert E Kaminski
Journal:  J Neuroimmune Pharmacol       Date:  2020-05-14       Impact factor: 4.147

6.  Repeated social defeat-induced neuroinflammation, anxiety-like behavior and resistance to fear extinction were attenuated by the cannabinoid receptor agonist WIN55,212-2.

Authors:  Sabrina Francesca Lisboa; Anzela Niraula; Leonardo Barbosa Resstel; Francisco Silveira Guimaraes; Jonathan P Godbout; John F Sheridan
Journal:  Neuropsychopharmacology       Date:  2018-04-17       Impact factor: 7.853

7.  Cannabinoid-Based Medicines and Multiple Sclerosis.

Authors:  Clementina Manera; Simone Bertini
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  CB2R induces a protective response for epileptic seizure via the PI3K 110α-AKT signaling pathway.

Authors:  Qingjun Cao; Xueyan Liu; Fenghua Yang; Hua Wang
Journal:  Exp Ther Med       Date:  2018-09-24       Impact factor: 2.447

9.  Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.

Authors:  Andrea Manterola; Ana Bernal-Chico; Raffaela Cipriani; Manuel Canedo-Antelo; Álvaro Moreno-García; Mar Martín-Fontecha; Fernando Pérez-Cerdá; María Victoria Sánchez-Gómez; Silvia Ortega-Gutiérrez; J Mark Brown; Ku-Lung Hsu; Benjamin Cravatt; Carlos Matute; Susana Mato
Journal:  Biochem Pharmacol       Date:  2018-08-01       Impact factor: 5.858

10.  Lysophosphatidylinositol, an Endogenous Ligand for G Protein-Coupled Receptor 55, Has Anti-inflammatory Effects in Cultured Microglia.

Authors:  Tomoki Minamihata; Katsura Takano; Mitsuaki Moriyama; Yoichi Nakamura
Journal:  Inflammation       Date:  2020-10       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.